Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma

References

• Calligaris-Cappio F. Biology of the malignant plasma cell. In: Gahrton G, Durie BGM, Samson DM, editors. Multiple myeloma and related disorders. London: Arnold; 2004. pp 58–73.
   Google Scholar
• Desikan R, Jagannath S, Richardson P, et al Multiple myeloma and other plasma cell dyscrasias. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer management: a multidisciplinary approach, 8th edn. New York, NY: CMP Healthcare Media; 2004. pp 727–745.
   Google Scholar
• Greipp PR, Kyle RA. Staging, kinetics and prognosis of multiple myeloma. In: Wiernik PH, Canellos GP, Dutcher JP, editors. Neoplastic diseases of the blood, 3rd edn. New York: Churchill Livingstone, Inc.; 1996. pp 537–559.
   Google Scholar
• Boccadoro M, Gavarotti P, Fossati G, et al Low plasma cell 3H thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984;58:689–696.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Witzig TE, Gonchoroff NJ. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Hematol 1985;20:289–292.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Witzig TE, Gonchoroff NJ, et al Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987;62:969.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Katzmann JA, O'Fallon M, et al Value of beta-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72:219–223.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Kumar S. Plasma Cell Labeling Index. In: Brown RD, Ho PJ, editors. Methods in molecular medicine. Multiple myeloma. Methods and protocolsTotowa, NJ: Humana Press; 2005. pp 25–35.
   Google Scholar
• Joshua D, Petersen A, Brown R, et al The labeling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol 1996;94:76–81.
   PubMed Web of Science ®Google Scholar
• Scudla V, Ordeltova M, Bacovsky J, et al The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Haematologica 2005;90:1713–1714.
   PubMed Web of Science ®Google Scholar
• Scudla V, Ordeltova M, Minarik J, et al Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Neoplasma 2006;53:199–205.
   Google Scholar
• Witzig TE, Timm M, Larson D, et al Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999;104:131–137.
   PubMed Web of Science ®Google Scholar
• Minařík J, Ščudla V, Ordeltová M, et al Evaluation of plasma cell propidium-iodide and annexin-V indices: their relation to prognosis in multiple myeloma. Biomed Pap 2005;149: 271–274.
   PubMedGoogle Scholar
• Kumar S, Timm M, Lacy MQ, et al Combining measurements of plasma cell apoptosis and proliferation in multiple myeloma identifies patients with poor survival. Blood (Suppl) 2005;106:3410 (Abstract).
   PubMed Web of Science ®Google Scholar
• Zemanova M, Scudla V, Adam Z, et al Low dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Neoplasma 2008;55:345–349.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   Google Scholar
• Durie BGM, Harousseau J-L, San Miguel JF, et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842–854.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel JF, Fonseca R, et al Development of an International Prognostic Index (IPI) for myeloma: report of the international myeloma working group. Hematol J 2003;4:542–544.
   Google Scholar
• Ordeltová M, Špidlová A, Ščudla V. Hodnocení S-fáze buněčného cyklu (CD38/propidium iodidového indexu) myelomových plasmocytů s pomocí průtokové cytometrie. Diagnoza 1999;1:11–15.
   Google Scholar
• Ščudla V, Ordeltová M. Vyšetření proliferačních charakteristik plasmocytů u mnohočetného myelomu. I. Přehled dosavadních metodických přístupů. Hemat Transf 1998;4:16–21.
   Google Scholar
• Ščudla V, Ordeltová M. Vyšetření proliferačních charakteristik plasmocytů u mnohočetného myelomu. II. Vztah ke klinickým a laboratorním ukazatelům nemoci Hemat Transf 1998;4: 22–28.
   Google Scholar
• Ordeltová M, Ščudla V, Špidlová A, et al Hodnocení apoptózy myelomových plazmocytů (annexin V/CD138 indexu) metodou průtokové cytometrie. Hematol Transf 2002;2:499–508.
   Google Scholar
• Chen-Kiang S. Multiple myeloma and plasma cells: cell cycle and apoptotic controls. In: Malpas JS, Bergsagel DE, KyleRA, Anderson KC, editors. Myeloma biology and management, 3rd edn. Philadelphia: Elsevier Inc.; 2004. pp 21–33.
   Google Scholar
• Boccadoro M, Durie BGM, Frutiger Y, et al Lack of Correlation between Plasma Cell Thymidine Labelling Index and serum beta-2-microglobulin in monoclonal gammopathies. Acta Haemat 1987;78:239–242.
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Gavarotti P, Ciaiolo C, et al Cytokinetic studies in human myeloma. Bas Appl Histochem 1986;30: 233–237.
   PubMedGoogle Scholar
• San Miguel JF, Garcia-Sanz R, Gonzales M, et al A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995;85:448–455.
   PubMed Web of Science ®Google Scholar
• Minařík J, Ščudla V, Ordeltová M, et al Hodnocení proliferačního a apoptotického indexu plazmatických buněk v průběhu mnohočetného myelomu. Vnitř Lék 2008;1:31–35.
   Google Scholar
• Xu JL, Lai R, Kinoshita T, et al Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002;55:530–534.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. The molecular biology of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, editors. Myeloma biology and management, 3rd edn. Philadelphia: Elsevier Inc.; 2004. pp 35–57.
   Google Scholar
• Greipp PR, Kyle RA. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983;62:166–171.
   PubMed Web of Science ®Google Scholar
• Schambeck CM, Wick M, Bartl R, et al Plasma cell proliferation in monoclonal gammopathies: measurement using BU-I antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. J Clin Pathol 1995;48:477–481.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Circulating plasma cells, labeling index, and angiogenesis in MGUS and smoldering multiple myeloma. IX International Myeloma Workshop. From MGUS to Myeloma, Focussed symposia: S33.
   Google Scholar
• Steensma DP, Gertz MA, Greipp PR, et al A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001;15:2522–2523.
   Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al High dose therapy improves the outcome of patients with multiple myeloma: the MRC Myeloma VII randomized study. New Eng J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Poon ML, Chng WJ. Is complete remission an important therapeutic aim in Multiple Myeloma? Cancer Ther 2008;6: 275–284.
   Google Scholar
• Blade J, Esteve J, Rives S, et al High dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Mar Transpl 2000;26:845–849.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, et al High dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized controlled trial from the Group Myelome Autogreffe. J Clin Oncol 2005;23:9227–9233.
   PubMed Web of Science ®Google Scholar
• Segeren CM, Sonneveld P, van der Holt B, et al Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101: 2144–2151.
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, et al Prospective comparison of autologous stem cell transplantation followed by dosereduced allograft (IFM 99-03 trial) with tandem autologous stem cell transplantation (IFM 99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–3480.
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Marmont F, Tribalto M, et al Early responder myeloma: kinetic studies identify a patient subgroup characterised by very poor prognosis. J Clin Oncol 1989;7: 119–125.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Lust J, O'Fallon WM, et al Plasma Cell Labeling Index and beta-2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;18:3382–3387.
   Google Scholar
• Ehlert JE, Kubbutat MHG. Apoptosis and its relevance in cancer therapy. Onkologie 2001;24:433–440.
   PubMed Web of Science ®Google Scholar
• Xu F, Gardner A, Tu Y, et al Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997;97:429–440.
   PubMed Web of Science ®Google Scholar
• Yang HH, Ma MH, Vescio RA, et al Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003;21:4239–4247.
   PubMed Web of Science ®Google Scholar
• Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 2008;20:97–103.
   PubMed Web of Science ®Google Scholar